Researchers found that lenacapavir reduced almost 100% reduction new HIV infections among participants who received it as a ...

Unfortunately, the Trump administration and the Republican majorities in Congress are putting access to lifesaving ...

Why a twice‑yearly injection might prove to be a good shot Lenacapavir is a first-in-class HIV drug that works by targeting ...

Thousands of adults age 50-plus are diagnosed with HIV every year, but an expanding menu of medications can help prevent ...

A landmark breakthrough in HIV prevention — a scientific feat decades in the making — received final approval from the Food ...

Rwanda is among the countries interested in Lenacapavir, a newly approved, long-acting preventive injection, though its cost is seemingly out of reach for many developing countries. Manufactured by US ...

President Donald Trump is removing a large portion of HIV funding he previously greenlit for a future without AIDs. For ...

Medical professionals Timothy Holtz and Teri Mills worked with AIDS patients in the 1990s, when treatments were few. With ...

Lenacapavir, an antiretroviral drug typically used to treat HIV infections, can also effectively prevent them, a phase 3 clinical trial has shown.

Lenacapavir’s cost as HIV treatment in the United States in 2023 was $42,250 per new patient per year. Oral PrEP options, on the other hand, can cost less than $4 a month.

In newly released data, lenacapavir, given via a twice-yearly injection, has shown remarkable effectiveness at eliminating HIV transmission during sexual contact. But its cost could be an issue.